Form 4: Director Robert Harrington Increases Stake in Cytokinetics

Director Robert Arthur Harrington acquired 191 shares of Cytokinetics common stock through the company's Director Equity in Lieu of Cash Retainer Program.

Summary

• Director Robert Arthur Harrington acquired 191 shares of Cytokinetics (CYTK) common stock on April 15, 2026.
• The shares were acquired at a price of $65.37 per share.
• The transaction was executed under the Director Equity in Lieu of Cash Retainer Program.
• Following this transaction, the director's total beneficial ownership is 18,930 shares.
• The acquired shares are fully vested.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director compensation that does not signal a change in company strategy or financial health.

Positives

• Director demonstrates alignment with shareholder interests by opting to receive equity in lieu of cash compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine Form 4 disclosure regarding director compensation.

Industry Context

StockSavvy.ai notes that director equity participation programs are standard practice in the biotechnology sector to align board incentives with long-term company performance.

Comparison to Industry Standards

• The use of equity in lieu of cash retainers is a common governance practice among mid-cap and large-cap pharmaceutical companies to preserve cash and incentivize directors.
• The transaction size is immaterial relative to the total market capitalization of Cytokinetics.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation transaction.

Next Steps

• None.

Key Dates

Keywords

Cytokinetics, CYTK, Insider Trading, Director Compensation, Equity Acquisition